|
WO1999001124A1
(en)
*
|
1996-12-03 |
1999-01-14 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
US20050043376A1
(en)
*
|
1996-12-03 |
2005-02-24 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
US6204388B1
(en)
|
1996-12-03 |
2001-03-20 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US6867305B2
(en)
|
1996-12-03 |
2005-03-15 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
FR2775187B1
(fr)
*
|
1998-02-25 |
2003-02-21 |
Novartis Ag |
Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
|
|
US6596875B2
(en)
|
2000-02-07 |
2003-07-22 |
James David White |
Method for synthesizing epothilones and epothilone analogs
|
|
US20050042275A1
(en)
*
|
1999-08-04 |
2005-02-24 |
Jean-Claude Sonntag |
Epothilone compositions
|
|
US7740841B1
(en)
*
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
|
US6489314B1
(en)
*
|
2001-04-03 |
2002-12-03 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
|
US6893859B2
(en)
*
|
2001-02-13 |
2005-05-17 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
|
IL156988A0
(en)
*
|
2001-02-20 |
2004-02-08 |
Bristol Myers Squibb Co |
Pharmaceutical compositions containing epothilone derivatives
|
|
CN1511036B
(zh)
*
|
2001-02-27 |
2010-05-05 |
诺瓦提斯公司 |
包含信号转导抑制剂和埃坡霉素衍生物的联合形式
|
|
DE60229922D1
(de)
*
|
2001-03-19 |
2009-01-02 |
Novartis Ag |
Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
|
|
US20070203346A1
(en)
*
|
2001-04-30 |
2007-08-30 |
Oregon State University |
Method for synthesizing epothilones and epothilone analogs
|
|
US6906188B2
(en)
*
|
2001-04-30 |
2005-06-14 |
State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University |
Method for synthesizing epothilones and epothilone analogs
|
|
TWI315982B
(en)
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
|
TWI287986B
(en)
*
|
2001-12-13 |
2007-10-11 |
Novartis Ag |
Use of Epothilones for the treatment of the carcinoid syndrome
|
|
EP1469847A1
(en)
*
|
2002-01-14 |
2004-10-27 |
Novartis AG |
Combinations comprising epothilones and anti-metabolites
|
|
EP1340498A1
(en)
*
|
2002-03-01 |
2003-09-03 |
Schering Aktiengesellschaft |
Use of epothilones in the treatment of brain diseases associated with proliferative processes
|
|
KR20040106422A
(ko)
*
|
2002-05-01 |
2004-12-17 |
노파르티스 아게 |
간암 및 다른 암 질병 치료용 에포틸론 유도체
|
|
US20040072882A1
(en)
*
|
2002-05-20 |
2004-04-15 |
Kosan Biosciences, Inc., A Delaware Corporation |
Methods to administer epothilone D
|
|
WO2004018478A2
(en)
|
2002-08-23 |
2004-03-04 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
US7649006B2
(en)
|
2002-08-23 |
2010-01-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
WO2004035050A1
(en)
*
|
2002-10-15 |
2004-04-29 |
Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College |
Use of epothilone derivatives for the treatment of hyperparathyroidism
|
|
CA2526285A1
(en)
*
|
2003-05-15 |
2004-12-23 |
Arqule, Inc. |
Inhibitors of p38 and methods of using the same
|
|
CA2530311A1
(en)
*
|
2003-06-27 |
2005-01-06 |
Novartis Ag |
Cancer treatment with epothilones
|
|
MXPA06002393A
(es)
*
|
2003-09-02 |
2006-06-20 |
Novartis Ag |
Tratamiento de cancer con epotilomas.
|
|
US20050171167A1
(en)
*
|
2003-11-04 |
2005-08-04 |
Haby Thomas A. |
Process and formulation containing epothilones and analogs thereof
|
|
US7829560B2
(en)
*
|
2004-07-08 |
2010-11-09 |
Arqule, Inc. |
1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
|
|
EP1809636A1
(en)
*
|
2004-10-19 |
2007-07-25 |
Arqule, Inc. |
Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
|
|
WO2006055742A1
(en)
*
|
2004-11-18 |
2006-05-26 |
Bristol-Myers Squibb Company |
Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
|
|
CA2607940C
(en)
|
2005-05-18 |
2009-12-15 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
|
ES2637592T3
(es)
|
2006-04-14 |
2017-10-13 |
Cell Signaling Technology, Inc. |
Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
|
|
US8168383B2
(en)
|
2006-04-14 |
2012-05-01 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
|
BRPI0711591A2
(pt)
|
2006-05-16 |
2011-11-16 |
Aegera Therapeutics Inc |
composto de ligação de domìnio bir da iap
|
|
US20100183600A1
(en)
*
|
2008-12-05 |
2010-07-22 |
Arqule, Inc. |
RAF Inhibitors and Their Uses
|
|
CA2756499A1
(en)
*
|
2009-03-25 |
2010-09-30 |
Novartis Ag |
Pharmaceutical composition containing a drug and sirna
|
|
SG182724A1
(en)
|
2010-02-12 |
2012-08-30 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
CA2799202C
(en)
|
2010-05-18 |
2016-07-05 |
Cerulean Pharma Inc. |
Compositions and methods for treatment of autoimmune and other diseases
|